Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1983 1
1988 1
2011 3
2012 3
2013 1
2014 3
2015 3
2016 4
2017 2
2018 3
2019 2
2020 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P, Teichner P, Elliot E, Boffito M, Murray M, Polli JW, Baker M, Ford SL, Han K, Russu A, Crauwels H, D'Amico RD, Spreen WR, van Wyk J. Patel P, et al. Among authors: russu a. Ther Adv Infect Dis. 2023 Dec 13;10:20499361231214626. doi: 10.1177/20499361231214626. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 38107552 Free PMC article. Review.
Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.
Samtani MN, Nandy P, Ravenstijn P, Remmerie B, Vermeulen A, Russu A, D'hoore P, Baum EZ, Savitz A, Gopal S, Hough D. Samtani MN, et al. Among authors: russu a. Br J Clin Pharmacol. 2016 Nov;82(5):1364-1370. doi: 10.1111/bcp.13050. Epub 2016 Jul 24. Br J Clin Pharmacol. 2016. PMID: 27333588 Free PMC article. Clinical Trial.
Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.
Timmers M, Sinha V, Darpo B, Smith B, Brown R, Xue H, Ferber G, Streffer J, Russu A, Tritsmans L, Solanki B, Bogert J, Van Nueten L, Salvadore G, Nandy P. Timmers M, et al. Among authors: russu a. J Clin Pharmacol. 2018 Jul;58(7):952-964. doi: 10.1002/jcph.1087. Epub 2018 Mar 5. J Clin Pharmacol. 2018. PMID: 29505101 Clinical Trial.
Continuous-time Markov modelling of flexible-dose depression trials.
Marostica E, Russu A, Gomeni R, Zamuner S, De Nicolao G. Marostica E, et al. Among authors: russu a. J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):625-38. doi: 10.1007/s10928-014-9389-6. Epub 2014 Oct 4. J Pharmacokinet Pharmacodyn. 2014. PMID: 25281421
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, Russu A, Janssens L, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S. Novak G, et al. Among authors: russu a. Alzheimers Res Ther. 2020 May 14;12(1):58. doi: 10.1186/s13195-020-00614-5. Alzheimers Res Ther. 2020. PMID: 32410694 Free PMC article. Clinical Trial.
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor.
Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, Bogert J, Stieltjes H, Shaw LM, Engelborghs S, Moechars D, Mercken M, Liu E, Sinha V, Kemp J, Van Nueten L, Tritsmans L, Streffer JR. Timmers M, et al. Among authors: russu a. Alzheimers Dement (N Y). 2016 Aug 24;2(3):202-212. doi: 10.1016/j.trci.2016.08.001. eCollection 2016 Sep. Alzheimers Dement (N Y). 2016. PMID: 29067308 Free PMC article.
30 results